Funding

The NADP can support you in finding project partners for projects aimed at the development of new antibiotics and alternative therapies (prevention and care) for human and animal health. You can contact the NADP Alliance Manager Schelto Korf via [email protected] with your questions about matchmaking and opportunities for your own project.

 

NADP
NADP Vouchers
SCOPE: support researchers and SMEs to bring novel antibiotics and alternatives a step closer to the clinic.

INFORMATION: https://nadp.nl/nadp-vouchers/

 

CARB-X
Request for proposal: Winter 2018
SCOPE: antibiotics, other therapeutics and preventatives & diagnostics and devices.

DEADLINE:

  • Round 1 | Submission closed
  • Round 2 | Expressions of interest (EOI) for Round 2 funding must be submitted on-line
    1 June 2018 through 8 June 2018 | 5:00 pm EST

INFORMATION: http://www.carb-x.org/scope

 

Belgian Health Care Knowledge Centre (KCE) & ZonMw
BeNeFIT Call open for Belgium-Netherlands Funding of International Trials
SCOPE: focuses on comparative effectiveness trials which show clear value for money and have the potential for return on investment, for research teams from Belgium and the Netherlands.

DEADLINE: 8 May 2018 | 2:00 pm

INFORMATION: https://www.zonmw.nl/nl/subsidies/openstaande-subsidieoproepen/detail/item/belgium-netherlands-funding-of-international-trials-benefit-call/

 

REPAIR Impact Fund
SCOPE: Novo Holdings is establishing the REPAIR Impact Fund to replenish the anti-infective pipeline and to combat antimicrobial resistance. The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund will invest in companies involved in discovering and early-stage development of therapies targeting resistant microorganisms.

DEADLINE: 15 May 2018

INFORMATION: https://www.repair-impact-fund.com/

 

Horizon2020 Work Programmes for 2018-2020
SCOPE: Horizon 2020 is the financial instrument of the European Commission that aims to drive economic growth and create jobs. Within Horizon 2020, research and innovation are coupled with an emphasis on excellent science, industrial leadership and tackling societal challenges.

Two thematic sections are specifically relevant for research on antimicrobial resistance and /or infectious diseases:

  • Health, demographic change and wellbeing
  • Food security, sustainable agriculture and forestry, marine, maritime and inland water research and the bioeconomy

DEADLINE: depends on thematic section

  • Health, demographic change and wellbeing
    Deadlines: first stage 23 January 2019, second stage 4 September 2019
  • Food security, sustainable agriculture and forestry, marine, maritime and inland water research and the bioeconomy
    Deadlines: first stage 13 February 2019, second stage 11 September 2019

INFORMATION: http://ec.europa.eu/programmes/horizon2020/en/h2020-section/food-security-sustainable-agriculture-and-forestry-marine-maritime-and-inland-water

 

Novartis Venture Fund
SCOPE: the Novartis Venture Fund makes equity investments in life science companies focussing on the development of novel therapeutics and platforms. Investments by the Novartis Venture Fund are made as equity participation typically as the lead or co-lead investor in a syndicate with a board seat. The Novartis Venture Fund has a relatively high amount of investments in the domain of infectious diseases.

DEADLINE: continuous application

INFORMATION: http://www.nvfund.com/

 

Partnering with AMR Centre (United Kingdom)
SCOPE: AMR Centre’s accelerates the development of new antimicrobial drugs and diagnostics. As such the AMR Centre works globally with companies and research institutions to support the development of their products from lead optimization through to Phase 2A. The AMR Centre aims to progress circa 5 new projects each year.

DEADLINE: continuous application

INFORMATION: http://www.amrcentre.com/partnering/